Sunel Israel is a private equity division of Sunel wherein the firm seeks out innovative Israeli companies.
Sunel Israel aims to bridge the gap between cutting-edge, early-stage Israeli companies and North American capital markets.
Serge Moyal from Sunel was instrumental in delisting Vaxil from the Tel Aviv exchange and listing the first ever Israeli Biotech company onto the Toronto Venture Exchange.
Vaxil was founded by Weizmann Institute scientists, Israel’s top research university, in order to provide an altogether novel approach to immunotherapy. Vaxil has diligently advanced its immunotherapy platform